Medivation and Astellas Pharma have enrolled the first patient in a global Phase III clinical trial that will evaluate the safety and efficacy of enzalutamide in patients with non-metastatic (often referred to as M0) castration-resistant prostate cancer (CRPC). Currently no prescription medicine is specifically approved for the treatment of patients with non-metastatic CRPC in the U.S. The randomized, double-blind, placebo-controlled, multi-national trial will enroll approximately 1,500 patient...